Rubius Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Liquidation

Rubius Therapeutics General Information

Description

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Contact Information

Website
www.rubiustx.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Primary Office
  • 399 Binney Street
  • Suite 300
  • Cambridge, MA 02139
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rubius Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 06-Apr-2023 00000 Completed Bankruptcy: Liquidation
4. IPO 18-Jul-2018 00000 00000 00.000 Completed Pre-Clinical Trials
3. Later Stage VC (Series C) 01-Mar-2018 00000 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 21-Jun-2017 $120M $145M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 27-Dec-2016 $25M $25M Completed Generating Revenue
To view Rubius Therapeutics’s complete valuation and funding history, request access »

Rubius Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 29,703,995 $0.001000 8% $0.6 $0.6 1x $0.6 39.94%
To view Rubius Therapeutics’s complete cap table history, request access »

Rubius Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer,
Drug Discovery
Cambridge, MA
6 As of 2022
00000
000000000000 00000

000000

um dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proide
0000 000000000
Ecublens, Switzerland
00 As of 0000
00000
0000000000 0 00000

000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Lyon, France
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rubius Therapeutics Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anokion Venture Capital-Backed Ecublens, Switzerland 00 00000 0000000000 0 00000
0000000 000000 Formerly VC-backed Lyon, France 00 00000 00000000 00000
000000000 Formerly VC-backed Rockville, MD 000 00000 000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
You’re viewing 5 of 24 competitors. Get the full list »

Rubius Therapeutics Patents

  • 120

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Rubius Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4103696-A1 Engineered erythroid cells including hla-g polypeptides and methods of use thereof Inactive 10-Feb-2020 0000000000
US-20210246426-A1 Engineered erythroid cells including hla-g polypeptides and methods of use thereof Inactive 10-Feb-2020 0000000000 0
CA-3159917-A1 Methods of generating enucleated erythroid cells using myo-inositol Pending 04-Nov-2019 0000000000
EP-4055149-A1 Methods of generating enucleated erythroid cells using myo-inositol Inactive 04-Nov-2019 0000000000
US-20210130780-A1 Methods of generating enucleated erythroid cells using myo-inositol Pending 04-Nov-2019 C12N5/0641
To view Rubius Therapeutics’s complete patent history, request access »

Rubius Therapeutics Board Members (15)

Name Representing Role Since
Catherine Sohn Self Board Member 000 0000
David Epstein Flagship Pioneering Chairman & Board Member 000 0000
Jonathan Symonds Ph.D Self Board Member 000 0000
Noubar Afeyan Ph.D Flagship Pioneering Board Member 000 0000
Pablo Cagnoni MD Self Chairman & Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Rubius Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rubius Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
135,000-square foot manufacturing facility in Rhode Island 31-Jul-2018 000000000 000 Buildings and Property 00000 000
To view Rubius Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial